ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis
NASDAQ:ADMA - US0008991046 - Common Stock
17.8 USD
+0.7 (+4.09%)
17.74 USD
-0.06 (-0.34%)
We assign a fundamental rating of 7 out of 10 to ADMA. ADMA was compared to 549 industry peers in the Biotechnology industry. While ADMA has a great health rating, its profitability is only average at the moment. ADMA is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make ADMA suitable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year ADMA was profitable.
ADMA had a positive operating cash flow in the past year.
In the past 5 years ADMA reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of ADMA (40.50%) is better than 98.91% of its industry peers.
With an excellent Return On Equity value of 55.37%, ADMA belongs to the best of the industry, outperforming 98.72% of the companies in the same industry.
ADMA has a better Return On Invested Capital (26.28%) than 98.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 40.5% | ||
| ROE | 55.37% | ||
| ROIC | 26.28% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ADMA has a better Profit Margin (45.01%) than 98.36% of its industry peers.
ADMA has a Operating Margin of 33.10%. This is amongst the best in the industry. ADMA outperforms 97.63% of its industry peers.
Looking at the Gross Margin, with a value of 52.58%, ADMA is in the better half of the industry, outperforming 76.87% of the companies in the same industry.
ADMA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.1% | ||
| PM (TTM) | 45.01% | ||
| GM | 52.58% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ADMA is creating value.
ADMA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ADMA has been increased compared to 5 years ago.
ADMA has a better debt/assets ratio than last year.
2.2 Solvency
ADMA has an Altman-Z score of 19.67. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
ADMA has a Altman-Z score of 19.67. This is amongst the best in the industry. ADMA outperforms 92.53% of its industry peers.
The Debt to FCF ratio of ADMA is 0.80, which is an excellent value as it means it would take ADMA, only 0.80 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.80, ADMA belongs to the best of the industry, outperforming 95.26% of the companies in the same industry.
ADMA has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
ADMA's Debt to Equity ratio of 0.19 is on the low side compared to the rest of the industry. ADMA is outperformed by 69.03% of its industry peers.
Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | 0.8 | ||
| Altman-Z | 19.67 |
ROIC/WACC2.66
WACC9.89%
2.3 Liquidity
ADMA has a Current Ratio of 6.58. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
ADMA has a Current ratio of 6.58. This is in the better half of the industry: ADMA outperforms 63.57% of its industry peers.
A Quick Ratio of 3.36 indicates that ADMA has no problem at all paying its short term obligations.
ADMA has a Quick ratio (3.36) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.58 | ||
| Quick Ratio | 3.36 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 285.71% over the past year.
The Revenue has grown by 65.15% in the past year. This is a very strong growth!
Measured over the past years, ADMA shows a very strong growth in Revenue. The Revenue has been growing by 70.84% on average per year.
EPS 1Y (TTM)285.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
Revenue 1Y (TTM)65.15%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%13.8%
3.2 Future
The Earnings Per Share is expected to grow by 32.01% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 22.46% on average over the next years. This is a very strong growth
EPS Next Y23.76%
EPS Next 2Y37.99%
EPS Next 3Y37.7%
EPS Next 5Y32.01%
Revenue Next Year19.84%
Revenue Next 2Y22.87%
Revenue Next 3Y25.19%
Revenue Next 5Y22.46%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 32.96 indicates a quite expensive valuation of ADMA.
Based on the Price/Earnings ratio, ADMA is valued cheaply inside the industry as 92.35% of the companies are valued more expensively.
ADMA is valuated rather expensively when we compare the Price/Earnings ratio to 26.76, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 18.70, which indicates a rather expensive current valuation of ADMA.
ADMA's Price/Forward Earnings ratio is rather cheap when compared to the industry. ADMA is cheaper than 93.08% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ADMA to the average of the S&P500 Index (34.91), we can say ADMA is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.96 | ||
| Fwd PE | 18.7 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ADMA is valued cheaper than 93.08% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ADMA is valued cheaply inside the industry as 92.90% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 47.07 | ||
| EV/EBITDA | 25.53 |
4.3 Compensation for Growth
ADMA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ADMA has a very decent profitability rating, which may justify a higher PE ratio.
ADMA's earnings are expected to grow with 37.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.39
PEG (5Y)N/A
EPS Next 2Y37.99%
EPS Next 3Y37.7%
5. Dividend
5.1 Amount
ADMA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
17.8
+0.7 (+4.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners90.24%
Inst Owner Change0.81%
Ins Owners2.35%
Ins Owner Change1.82%
Market Cap4.25B
Analysts82
Price Target29.64 (66.52%)
Short Float %6%
Short Ratio4.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.83%
Min EPS beat(2)-31.17%
Max EPS beat(2)-8.5%
EPS beat(4)2
Avg EPS beat(4)8.19%
Min EPS beat(4)-31.17%
Max EPS beat(4)59.31%
EPS beat(8)4
Avg EPS beat(8)-15.66%
EPS beat(12)7
Avg EPS beat(12)-6.3%
EPS beat(16)10
Avg EPS beat(16)-4.09%
Revenue beat(2)1
Avg Revenue beat(2)-0.57%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)2.16%
Revenue beat(4)3
Avg Revenue beat(4)7.87%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)21.61%
Revenue beat(8)7
Avg Revenue beat(8)6.02%
Revenue beat(12)11
Avg Revenue beat(12)6.72%
Revenue beat(16)15
Avg Revenue beat(16)7.22%
PT rev (1m)-1.46%
PT rev (3m)12.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.98%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)1.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.96 | ||
| Fwd PE | 18.7 | ||
| P/S | 9.25 | ||
| P/FCF | 47.07 | ||
| P/OCF | 41.98 | ||
| P/B | 11.38 | ||
| P/tB | 11.5 | ||
| EV/EBITDA | 25.53 |
EPS(TTM)0.54
EY3.03%
EPS(NY)0.95
Fwd EY5.35%
FCF(TTM)0.38
FCFY2.12%
OCF(TTM)0.42
OCFY2.38%
SpS1.92
BVpS1.56
TBVpS1.55
PEG (NY)1.39
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 40.5% | ||
| ROE | 55.37% | ||
| ROCE | 33.26% | ||
| ROIC | 26.28% | ||
| ROICexc | 31.16% | ||
| ROICexgc | 31.49% | ||
| OM | 33.1% | ||
| PM (TTM) | 45.01% | ||
| GM | 52.58% | ||
| FCFM | 19.65% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | 0.8 | ||
| Debt/EBITDA | 0.45 | ||
| Cap/Depr | 138.39% | ||
| Cap/Sales | 2.38% | ||
| Interest Coverage | 11.85 | ||
| Cash Conversion | 63.28% | ||
| Profit Quality | 43.66% | ||
| Current Ratio | 6.58 | ||
| Quick Ratio | 3.36 | ||
| Altman-Z | 19.67 |
F-Score7
WACC9.89%
ROIC/WACC2.66
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)285.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
EPS Next Y23.76%
EPS Next 2Y37.99%
EPS Next 3Y37.7%
EPS Next 5Y32.01%
Revenue 1Y (TTM)65.15%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%13.8%
Revenue Next Year19.84%
Revenue Next 2Y22.87%
Revenue Next 3Y25.19%
Revenue Next 5Y22.46%
EBIT growth 1Y243.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.39%
EBIT Next 3Y41.12%
EBIT Next 5Y36.1%
FCF growth 1Y247.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y309.9%
OCF growth 3YN/A
OCF growth 5YN/A